BIEFFE MEDITAL SPA

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

Baxter International Inc., founded in 1931, is a healthcare leader with 60,000 global employees, offering critical care, hospital care, and medication delivery. Under CEO José E. Almeida, it generates $15.1bn in revenue, focusing on renal care, surgical solutions, and biotechnology to sustain lives and drive innovation.

US drug shortages decreased to 277 in Sept 2024, with 50% lasting 2+ years. Key shortages include ADHD meds, pain treatments, chemotherapy drugs, insulin, and diabetes/weight loss meds. IV fluids added due to Hurricane Helene impacting Baxter's production.

The Centers for Disease Control and Prevention issued an advisory to health care providers, laboratory professionals, and others in health care.

Baxter received FDA approval to extend the shelf life of over 50 IV and irrigation products by up to 12 months, now allowing a 24-month expiry for products made before September 2024. A temporary bridge moved over 825 truckloads of finished products from Baxter's North Cove facility, with a second bridge opening in early November. Baxter anticipates restarting its primary IV solutions line by mid- to late November. Nine Baxter plants are supplementing North Cove's output to stabilize U.S. supply levels. Conservation efforts for IV and peritoneal dialysis solutions remain crucial.

The FDA added Dextrose 70% IV solution, Lactated Ringers IV Solution, and Peritoneal Dialysis Solution to the Drug Shortage Database due to Hurricane Helene's impact on Baxter. The FDA issued immediate guidance allowing temporary compounding of shortage drugs without FDA approval, encouraging record-keeping and adverse event reporting. The agency awaits stability data to potentially extend expiry dates on IV fluids.

A Florida IV fluid plant remains functional after Hurricane Milton, crucial as North Carolina plants are out due to Hurricane Helene, causing nationwide shortages. Hospitals are rationing IV fluids, impacting patients like those with sepsis and dialysis needs.

Baxter increases IV fluid allocations amid shortages; GSK to settle 80,000 Zantac lawsuits for up to $2.2B.

Hurricane Helene damaged a North Carolina plant, leading to IV fluid shortages in U.S. hospitals. Baxter and B. Braun, major suppliers, are redirecting supplies from overseas. The FDA authorized imports from Baxter plants in Canada, Ireland, the UK, and China. Hospitals are postponing surgeries and rationing IV fluids, impacting patients like those with sepsis and dialysis needs.

Pfizer wins RSV vaccine patent fight; Baxter uncertain when hurricane-hit plant will reopen.